Firebrick Pharma (ASX:FRE) is floating on the ASX today. Here's what you need to know

Here are all the details on the stock set to hit the ASX this afternoon.

| More on:
Female scientist working in laboratory for Race Oncology

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Firebrick Pharma will debut on the ASX at 12:30 pm AEDT today
  • The company is developing a nasal spray to help treat the common cold. It's product will also undergo a COVID-19 trial
  • Shares in the company were offered for 20 cents a apiece during its IPO

Shares in Firebrick Pharma Limited (ASX: FRE) – a company developing a virus-killing nasal spray – will float on the ASX this afternoon.

The stock will hit the decks at 12:30 pm AEDT after the company raised $7 million through its initial public offering (IPO). Under its prospectus, Firebrick shares were offered for 20 cents apiece.

Here's what you need to know ahead of the pharmaceutical development firm's ASX debut.

All the details on Firebrick Pharma's ASX IPO and float

Shares in Firebrick Pharma will list on the ASX this afternoon after its fully subscribed IPO.

The float follows nearly 10 years of development of its patented nasal spray, Nasodine, with povidone-iodine as its active ingredient, which is designed to kill the common cold where it starts – in the nose.

Nasodine has undergone 3 human clinical trials, confirming it is safe and well-tolerated in adults.

Additionally, a phase 3 clinical trial found the product can significantly reduce the severity of the common cold in people with strong symptoms, confirmed viral infections, or who started treatment within 24 hours of symptoms appearing,

According to Firebrick co-founder and chair Dr Peter Molloy, with one more phase 3 clinical trial, Nasodine could be approved as a treatment for the common cold in adults. That clinical trial is set to go ahead in 2022.

If successful, the company will then seek approvals from regulators in its target markets of Australia, the United States, and Europe.

If all goes to plan, Nasodine could launch in Australia in 2023.

On top of its potential to treat the common cold, the company is planning a phase 2 trial to find if its product can help treat COVID-19.

The trial aims to show the product can reduce shedding of the COVID-19 virus. It will go ahead this year in South Africa.

The funds raised in Firebrick's ASX IPO will go towards ongoing clinical trials, marketing, and operating costs.

Molloy has previously been a marketer and CEO of 4 biotechnology firms, including Race Oncology Ltd (ASX: RAC). Over his career, he has helped launch Betadine Sore Throat Gargle.

Firebrick co-founder, executive director, and chief operating officer (COO), Dr Stephen Goodall, used to be COO of formerly-ASX-listed Viralytics Limited.

At its offer price, the company is expected to list with a market capitalisation of around $33.8 million.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on IPOs

An arrow going upwards with a road sign saying 'IPO ahead'.

Should you buy into an IPO or wait until shares start trading on the ASX?

IPOs can be exciting, but also dangerous for investors.

Read more »

A female miner wearing a high vis vest and hard hard smiles and holds a clipboard while inspecting a mine site with a colleague.

ASX IPO alert: Blockbuster copper listing coming soon

Here's what you need to know about this upcoming IPO.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.

Fewer ASX IPOs in 2023, but here's how they've performed

We reveal the top 10 new listings by size and how their share prices have changed to date.

Read more »

IPO written in yellow and stuck in the air.
Materials Shares

Rich listers are buying into the IPO of ASX lithium explorer Kali Metals

There's a new lithium share in town. Here's what you need to know.

Read more »

IPO written in circles with a man holding a smartphone and a laptop open.
International Stock News

The highs and lows of the Instacart $11 billion IPO

Here is a closer look at the latest company to hit the Nasdaq exchange.

Read more »

Two businessmen shake hands against a tech backdrop, indicating a company IPO or a merger between two technology stocks.

This $85 billion company is about to start trading on the Nasdaq. Here's what you need to know

Arm is set to join the ranks of other AI high-flyers on the Nasdaq tonight.

Read more »

A businessman hugs his computer and smiles.
Materials Shares

The ASX welcomed a new lithium stock today, and it's up 50%!

Investors have been getting excited about this new lithium stock today.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Redox share price drops after IPO

One of the biggest IPOs in some time has taken place on the ASX today.

Read more »